CN104364257B - 5‑酰基‑6,7‑二氢噻吩并[3,2‑c]吡啶类化合物对胰腺及相关癌症的治疗作用 - Google Patents

5‑酰基‑6,7‑二氢噻吩并[3,2‑c]吡啶类化合物对胰腺及相关癌症的治疗作用 Download PDF

Info

Publication number
CN104364257B
CN104364257B CN201380025406.9A CN201380025406A CN104364257B CN 104364257 B CN104364257 B CN 104364257B CN 201380025406 A CN201380025406 A CN 201380025406A CN 104364257 B CN104364257 B CN 104364257B
Authority
CN
China
Prior art keywords
alkyl
purposes
pharmaceutically acceptable
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380025406.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104364257A (zh
Inventor
M·D·雷士
J·F·格利克曼
E·彼得洛娃
O·奥尔费利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Memorial Sloan Kettering Cancer Center
Original Assignee
Rockefeller University
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University, Memorial Sloan Kettering Cancer Center filed Critical Rockefeller University
Publication of CN104364257A publication Critical patent/CN104364257A/zh
Application granted granted Critical
Publication of CN104364257B publication Critical patent/CN104364257B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201380025406.9A 2012-03-23 2013-03-14 5‑酰基‑6,7‑二氢噻吩并[3,2‑c]吡啶类化合物对胰腺及相关癌症的治疗作用 Expired - Fee Related CN104364257B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261614954P 2012-03-23 2012-03-23
US61/614,954 2012-03-23
PCT/US2013/031311 WO2013142253A2 (en) 2012-03-23 2013-03-14 TREATMENT OF PANCREATIC AND RELATED CANCERS WITH 5-ACYL-6,7-DIHYDROTHIENO[3,2-c]PYRIDINES

Publications (2)

Publication Number Publication Date
CN104364257A CN104364257A (zh) 2015-02-18
CN104364257B true CN104364257B (zh) 2017-03-01

Family

ID=49223442

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380025406.9A Expired - Fee Related CN104364257B (zh) 2012-03-23 2013-03-14 5‑酰基‑6,7‑二氢噻吩并[3,2‑c]吡啶类化合物对胰腺及相关癌症的治疗作用

Country Status (7)

Country Link
US (3) US9242994B2 (enExample)
EP (1) EP2828267B1 (enExample)
JP (1) JP6117334B2 (enExample)
CN (1) CN104364257B (enExample)
AU (1) AU2013235487B2 (enExample)
CA (1) CA2868356C (enExample)
WO (1) WO2013142253A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2828267B1 (en) * 2012-03-23 2019-10-30 Memorial Sloan-Kettering Cancer Center TREATMENT OF PANCREATIC AND RELATED CANCERS WITH 5-ACYL-6,7-DIHYDROTHIENO[3,2-c]PYRIDINES
US20200062776A1 (en) * 2016-06-16 2020-02-27 Memorial Sloan-Kettering Cancer Center Hedgehog acyltransferase inhibitors and uses thereof
CA3180317A1 (en) * 2020-04-17 2021-10-21 The Trustees Of Indiana University Small molecule antiviral drug treatment for human papillomavirus infections
WO2024258849A2 (en) 2023-06-13 2024-12-19 The Trustees Of Indiana University Small molecule antiviral drug treatment for human papillomavirus infections
WO2025153715A1 (en) * 2024-01-19 2025-07-24 Scenic Biotech Bv Heterocyclic pla2g15 inhibitors and their use in therapy, in the treatment of diseases characterized by lysosomal dysregulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101133063A (zh) * 2005-03-02 2008-02-27 默克专利有限公司 噻吩并吡啶衍生物及其作为hsp90调节剂的用途
WO2009124746A1 (en) * 2008-04-09 2009-10-15 Grünenthal GmbH Substituted sulfonamide derivatives

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2315274A1 (fr) 1975-06-27 1977-01-21 Parcor Nouveaux derives de la thieno (2,3-c) pyridine, leur preparation et leurs applications
US4749692A (en) 1977-06-22 1988-06-07 Sanofi, S.A. Therapeutic compositions having anti-thrombotic and anti-blood-platelet-aggregating activity
EP0973778A1 (en) * 1997-03-07 2000-01-26 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
MX2009012610A (es) * 2007-05-22 2009-12-11 Astellas Pharma Inc Compuesto de tetrahidroisoquinolina 1-sustituido.
WO2009073203A1 (en) 2007-12-04 2009-06-11 Amgen Inc. Trp-m8 receptor ligands and their use in treatments
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
ES2392758T3 (es) * 2008-10-24 2012-12-13 Grünenthal GmbH 4,5,6,7-Tetrahidrotienopiridinas sustituidas como moduladores de KCNQ2/3 para el tratamiento del dolor, la epilepsia y la incontinencia urinaria
MX2011009314A (es) 2009-03-05 2011-10-11 Astellas Pharma Inc Compuesto de quinoxalina.
EP2286808A1 (en) * 2009-08-18 2011-02-23 Rheinische Friedrich-Wilhelms Universität Cytohesin inhibitors
DE102010013716A1 (de) 2010-03-31 2011-10-06 Rheinische Friedrich-Wilhelms-Universität Bonn Körperschaft des öffentlichen Rechts Verwendung von Cytohesin-Inhibitoren
EP2828267B1 (en) * 2012-03-23 2019-10-30 Memorial Sloan-Kettering Cancer Center TREATMENT OF PANCREATIC AND RELATED CANCERS WITH 5-ACYL-6,7-DIHYDROTHIENO[3,2-c]PYRIDINES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101133063A (zh) * 2005-03-02 2008-02-27 默克专利有限公司 噻吩并吡啶衍生物及其作为hsp90调节剂的用途
WO2009124746A1 (en) * 2008-04-09 2009-10-15 Grünenthal GmbH Substituted sulfonamide derivatives

Also Published As

Publication number Publication date
US9943507B2 (en) 2018-04-17
US20170252328A1 (en) 2017-09-07
HK1207367A1 (en) 2016-01-29
CA2868356C (en) 2020-06-23
AU2013235487A1 (en) 2014-10-09
CA2868356A1 (en) 2013-09-26
US20160136142A1 (en) 2016-05-19
WO2013142253A2 (en) 2013-09-26
US20150105419A1 (en) 2015-04-16
EP2828267A4 (en) 2015-10-28
US9597320B2 (en) 2017-03-21
WO2013142253A3 (en) 2013-11-14
JP6117334B2 (ja) 2017-04-19
AU2013235487B2 (en) 2017-09-07
JP2015512399A (ja) 2015-04-27
EP2828267B1 (en) 2019-10-30
EP2828267A2 (en) 2015-01-28
US9242994B2 (en) 2016-01-26
CN104364257A (zh) 2015-02-18

Similar Documents

Publication Publication Date Title
JP6887996B2 (ja) Ｔｅａｄ転写因子自己パルミトイル化阻害剤
Tanjoni et al. PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments
US9943507B2 (en) Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines
EP3786167B1 (en) Diaryl macrocyclic compound and pharmaceutical composition, and use thereof
CN114760994A (zh) HIF-2α的抑制剂
Lindberg et al. Chemical, biochemical, cellular, and physiological characterization of Leucettinib-21, a Down syndrome and Alzheimer’s disease drug candidate
RS53599B1 (sr) Piridon derivati za modulaciju stresom aktiviranog sistema proteinskih kinaza
JP2018508563A (ja) Ｕｓｐ７阻害剤化合物及び使用方法
CN103476411B (zh) 标靶人类胸腺核苷酸激酶诱导恶性肿瘤中的dna修复毒性
JP6479669B2 (ja) 耐性変異型９０ｋＤａ熱ショックタンパク質
CA2890108C (en) Method for treating prostate cancer
US11773096B2 (en) Small-molecule PI5P4K alpha/beta inhibitors and methods of treatment using same
HK1207367B (en) Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines
Brukner C-1027 Taiho Pharmaceutical Co Ltd
Li et al. Development of novel PRMT7 inhibitors for the treatment of prostate cancer
US20250122193A1 (en) Novel pyridocarbazolium compounds and medical uses thereof
WO2013192301A1 (en) Imidazo bicyclic imminium compounds as antitumor agents
WO2021155748A1 (en) Inhibitors of malarial and plasmodium falciparum hexose transporter and uses thereof
US20240150333A1 (en) Taf1 inhibitors
Tjin Mechanism-and Structure-Based Development of Small Molecule Inhibitors Against Therapeutically Important Enzymes
HK1224702A1 (en) Resistant mutant 90 kda heat shock protein

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1207367

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1207367

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170301

Termination date: 20210314